[Edaily Reporter KIM JI-WAN ] As Moderna and Merck’s personalized mRNA cancer vaccines have yielded positive preliminary results in Phase 3 clinical trials, the technological capabilities of NeoGenLogic—a subsidiary of SCL Science(246960) that is developing AI-based personalized cancer vaccines in South Korea—are once again drawing attention.

According to foreign media reports on the 19th (local time), the personalized mRNA cancer vaccine currently being jointly developed by Moderna and Merck was shown in a Phase 3 clinical trial involving high-risk melanoma patients to significantly extend progression-free survival compared to a group treated with Keytruda alone.

These results are seen as significantly increasing the potential for the commercialization of personalized cancer vaccines, which analyze mutations occurring in each patient’s tumor to identify neoantigens optimized for the individual and, based on this, induce the immune system to attack cancer cells.

As global big pharma companies accelerate the development of personalized cancer vaccines, attention is also turning to NeoGenLogic, which possesses a next-generation neoantigen discovery platform.

NeoGenLogic possesses “DeepNeo,” an AI-based cancer vaccine design platform jointly developed with Professor Choi Jeong-kyun’s research team at KAIST’s Department of Bio and Brain Engineering, as well as “DeepDependency,” a single-cell big data platform.

In particular, DeepNeo is characterized by its ability to simultaneously analyze and predict not only T-cell but also B-cell immune responses—a feature that sets it apart from the cancer vaccine technologies of existing global pharmaceutical companies.

Conventional personalized cancer vaccine development has primarily focused on identifying neoantigens capable of inducing T-cell responses that directly attack cancer cells. In contrast, Neogen Logic has developed the world’s first algorithm to quantitatively predict B-cell responsiveness to neoantigens, thereby securing technology to screen for candidate compounds capable of simultaneously stimulating both the T-cell and B-cell immune systems.

It has been confirmed that stimulating both the T-cell and B-cell immune systems simultaneously increases the probability of inducing an immune response by more than 4.7 times compared to conventional methods. The results of this research were published in the international academic journal *Science Advances*.

Based on this technology, NeogenLogic has secured patents in South Korea, Japan, and China and is expanding its global patent portfolio to major markets such as the United States and Europe.

The company is accelerating the development of personalized cancer vaccine candidates using DeepNeo and is proceeding with its development schedule with the goal of submitting an Investigational New Drug (IND) application by 2027.

An SCL Science official stated, “The success of Moderna and Merck’s Phase 3 clinical trials is a decisive milestone demonstrating that personalized cancer vaccines have entered a realistic stage of commercialization,” adding, “Based on NeoGenLogic’s unique integrated AI analysis technology for T and B cells, we will proceed without delay with our plan to file an Investigational New Drug (IND) application in 2027, and we plan to hold a briefing in September to provide detailed information on the exact timeline.”